Successful IPO of STENTYS on NYSE Euronext Paris

The Public Offering was more than twice oversubscribed and the Global Placement 1.1 time

- Offering Price: €12.00 per share
- Amount of the offer: €22.7 million, before the exercise of the over-allotment option
- Trading to begin on October 25th, 2010 in the form of promises of shares

STENTYS, a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), has announced the final terms of its initial public offering (IPO) on Euronext Paris (Compartment C, ISIN: FR0010949404 – Ticker: STNT).

As a result of this IPO, STENTYS will raise approximately €22.7 million, which will be used to commercialize its innovative stents in Europe, and to obtain regulatory approvals for their commercialization in the United States of America.

Commenting on the results of the initial public offering, Mr. Gonzague Issenmann, Chief Executive Officer and Co-Founder of STENTYS said: “We are very pleased with the success of STENTYS’ IPO. We would like to thank our existing and new shareholders, and especially individual shareholders.”

Prof. Jacques Séguiie, Chairman and Co-Founder of STENTYS added: “Our innovative technology convinced the investors. We now have the means to establish STENTYS’ self-apposing stent as the reference treatment for AMI, a $2.3 billion market.”

GENERAL TERMS OF THE OFFERING

Offering Price

- The offering price for the public offering and the global placement is €12.00 per share in the middle of the initial indicative range.
- The price of the offer results in a market capitalization of STENTYS of approximately €87 million after the capital increase.

Size of the Offer and gross proceeds of the global offering (not including the over-allotment option)

- The Company decided not to exercise the extension clause and consequently issue a total of 1 893 939 new shares.
- The gross proceeds will total approximately €22.7 million.
- STENTYS granted Société Générale an over-allotment option that can be exercised between October 22nd, 2010 and November 19th, 2010 allowing the subscription of a maximum of 139 262 new shares, i.e. an approximate amount of €1.7 million.

Breakdown of the Offering (not including the over-allotment option)

In light of a strong demand from individual investors, it was decided to double the number of shares dedicated to the Public Offering leading to the following breakdown of the Offer:
STENTYS

- Global Placement: 1,498,500 shares were placed in France and in certain other countries outside the United States of America (i.e. approximately €18 million or 79% of the offered shares).
- Public Offering in France: 395,439 shares were placed in the French public offering (i.e. approximately €4.7 million or 21% of the offered shares).
- For the Public Offering, A1 orders will be 100% satisfied and A2 orders will be 95% satisfied.

Offering Timetable

- Trading on Euronext Paris (Compartment C) to begin on October 25th, 2010 in the form of promises of shares.
- Settlement and delivery of the shares are expected to take place on October 27th, 2010.
- November 19th, 2010: Deadline for exercising the over-allotment option and end of possible stabilization period.

Banking syndicate

Société Générale
Corporate & Investment Banking
Lead Manager and Bookrunner

Piper Jaffray
Co-Lead Manager

Allegra Finance
Counsel for STENTYS

Member of the placement syndicate

Public information

The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 25 rue de Choiseul, 75002 Paris.

Copies of the Prospectus filed by the Autorité des Marches Financiers on October 12th, 2010 under the number 10-362 are available free of charge from the Company and from the Lead Underwriter and the Co-underwriter. The Prospectus may be viewed on the websites of the Company (www.stentys.com) and of the AMF (www.amf-france.org).

The attention of investors is drawn to Section 4 “Risk Factors” of the “Document de Base” registered with the AMF and to Section 2 “Risk Factors” contained in the “Note d’opération”, and, in particular, to the specific risks related to the two Company’s licensing agreements.

About STENTYS:

Based in Paris (France) and Princeton, N.J. (USA), the STENTYS Company has developed a new generation of stents to treat acute myocardial infarction. Founded by Jacques Séguin, Professor of Cardiac Surgery, and Gonzague Issenmann, STENTYS received the CE mark for its flagship products in 2010. Its self-apposing stents adapt the anatomic changes of the arteries in the post-infarction phase and prevents conventional stents mal-apposition problems. STENTYS has started its marketing activities in several European countries.

More information about the company on the website: www.stentys.com

Citigate
Dewe Rogerson

Analysts
Agnès Villeret - Tel: +33 (0)1 53 32 78 95 - agnes.villeret@citigate.fr
Press
Servane Taslé – Tél : +33 (0)1 53 32 78 94 / (06) 66 58 84 28 – servane.tasle@citigate.fr
Lucie Larguier - Tel : +33 (0)1 53 32 84 75 - lucie.larguier@citigate.fr

Notice

This press release, together with the material set forth herein, does not constitute an offer of securities for sale or the solicitation of an offer to purchase securities of STENTYS in any jurisdiction. The dissemination, publication or distribution of this press release in certain countries can constitute a violation of the applicable legal and regulatory provisions. Consequently, persons physically located in these countries and in which this press release is disseminated, distributed or published must obtain information regarding these possible local restrictions, and comply with them.

In particular:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any financial instruments in the United States of America. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States of America absent registration or an exemption from the registration requirements of the Securities Act. The Company does not intend to register this offering in all or in part or to make a public offer of securities in the United States of America.